Clinical trials
Observational Multiple Sclerosis trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
58 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2006 | 1 |
| 2007 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 6 |
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 7 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
| Unknown status | 11 |
| Recruiting | 11 |
| Active, not recruiting | 3 |
| Enrolling by invitation | 2 |
| Terminated | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biogen | 6 |
| Fondazione Don Carlo Gnocchi ETS | 4 |
| IRCCS San Raffaele | 4 |
| Bayer | 3 |
| Neuromed IRCCS | 3 |
| Novartis Pharmaceuticals | 3 |
| EMD Serono | 2 |
| Fondazione Italiana Sclerosi Multipla | 2 |
| IRCCS Centro Neurolesi Bonino Pulejo | 2 |
| IRCCS San Camillo, Venezia, Italy | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis | 58 |
| Parkinson Disease | 10 |
| Stroke | 5 |
| Multiple Sclerosis, Relapsing-Remitting | 4 |
| Brain Injuries | 3 |
| Demyelinating Diseases | 3 |
| Nervous System Diseases | 3 |
| Alzheimer Disease | 2 |
| Autoimmune Diseases | 2 |
| Epilepsy | 2 |
Trials
Showing 1 to 25 of 58. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.